STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVCR
  4. [Form 4] NovoCure Ltd Insider Trading Activity

Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovoCure Ltd’s former Chief Executive Officer Ashley Cordova reported a mix of equity award activity and related tax withholding. On February 28, 2026, Cordova acquired 23,818 Ordinary Shares at $0.00 per share from the vesting of performance-based restricted stock units.

On February 27 and March 2, 2026, Cordova disposed of Ordinary Shares in several tax-withholding dispositions tied to restricted stock unit vesting. These non-discretionary transactions withheld 11,541 shares at $13.75, and 2,410 and 7,228 shares at $13.67, to cover tax obligations as approved under Rules 16b-3(e) and 16b-3(d)(1).

Positive

  • None.

Negative

  • None.
Insider Cordova Ashley
Role Former Chief Executive Officer
Type Security Shares Price Value
Tax Withholding Ordinary Shares 2,410 $13.67 $33K
Tax Withholding Ordinary Shares 7,228 $13.67 $99K
Grant/Award Ordinary Shares 23,818 $0.00 --
Tax Withholding Ordinary Shares 11,541 $13.75 $159K
Holdings After Transaction: Ordinary Shares — 447,436 shares (Direct)
Footnotes (1)
  1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Represents vesting of performance-based restricted stock units.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cordova Ashley
(Last) (First) (Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115
(Street)
WAYNE PA 19087
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Former Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 02/27/2026 F 11,541(1) D $13.75 426,028 D
Ordinary Shares(2) 02/28/2026 A 23,818 A $0.00 449,846 D
Ordinary Shares 03/02/2026 F 2,410(1) D $13.67 447,436 D
Ordinary Shares 03/02/2026 F 7,228(1) D $13.67 440,208 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).
2. Represents vesting of performance-based restricted stock units.
Remarks:
Steven Robbins, as attorney in fact for Cordova, Ashley 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did NovoCure (NVCR) report for Ashley Cordova?

NovoCure reported that former CEO Ashley Cordova had performance-based restricted stock units vest, adding 23,818 Ordinary Shares, and then had several related tax-withholding share dispositions to satisfy tax obligations tied to those equity awards.

Were Ashley Cordova’s NovoCure (NVCR) share disposals open-market sales?

The disposals were tax-withholding transactions, not open-market sales. Shares were withheld by NovoCure to cover tax liabilities from restricted stock unit vesting, characterized as non-discretionary and approved under Rules 16b-3(e) and 16b-3(d)(1).

How many NovoCure (NVCR) shares vested for Ashley Cordova in this Form 4?

The filing shows 23,818 Ordinary Shares acquired at $0.00 per share, representing the vesting of performance-based restricted stock units. This grant/award acquisition is reported under transaction code A for non-derivative securities.

What were the share amounts and prices for NovoCure (NVCR) tax-withholding dispositions?

NovoCure withheld 11,541 Ordinary Shares at $13.75, and 2,410 plus 7,228 shares at $13.67, all reported as tax-withholding dispositions under code F to pay exercise price or tax liabilities.

What role did Ashley Cordova hold at NovoCure (NVCR) during these transactions?

The reporting person, Ashley Cordova, is identified as NovoCure’s Former Chief Executive Officer. The Form 4 covers her direct ownership transactions in Ordinary Shares related to equity award vesting and associated tax withholding.

How are NovoCure (NVCR) Form 4 tax-withholding transactions described?

They are described as payments of exercise price or tax liability by delivering securities, using transaction code F. Footnotes state the share amounts were required to be withheld to cover tax obligations in connection with restricted stock unit vesting and were not discretionary.